Glibomet coated tablets №40


Manufacturer: Germany

Type II diabetes mellitus (insulin-independent diabetes mellitus-INCD) with insufficient effectiveness of diet therapy or diet therapy with the use of sulfonylureas or biguanides



Glibomet Composition and form of release:

tab. p / o, No. 40

No. UA / 7166/01/01 from 18.10.2007 to 18.10.2012

tab. p / o, No. 100

Other ingredients:

corn starch, highly dispersed silicon dioxide, microcrystalline cellulose, gelatin, glycerin, talc, magnesium stearate, cellulose acetate phthalate, diethyl phthalate.

Pharmacological properties:

Pharmacodynamics. Glibomet is a combination of glibenclamide and metformin. The combined effect of these two components is that there is a stimulation of the process of secretion of endogenous insulin a, caused by glibenclamide, and a significant increase in the utilization of glucose by muscle tissue due to the direct effect of metformin on it. This combination leads to a significant synergistic effect, which allows you to reduce the amount of each component in one dose, thus avoiding too strong stimulation of beta cells, with a subsequent decrease in the risk of their functional failure and a significant increase in the safety of use, as well as a decrease in the incidence of side effects.


Glibomet Indications:

non-insulin dependent diabetes mellitus when it is impossible to normalize blood glucose levels using diet therapy alone or diet therapy in combination with treatment with sulfonylurea derivatives or biguanides.

Glibomet Application:

the daily dose, route of administration and duration of treatment are determined by the physician in accordance with the patient’s metabolic state. For adults, the initial dose is 2 tablets per day (1 tablet in the morning and in the evening with meals), but in no case should it exceed 6 tablets (2 tablets are taken 3 times a day with meals). The daily dose can then be gradually reduced until a minimum dose is reached that is sufficient to control glucose levels.